Tizanidine Hydrochloride Capsule
Product Images NDC 68788-8776

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 68788-8776). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

A Yellow Rectangular Box With Black Textdescription Automatically Generated (Tizanidine Hydrochloride Capsules 4mg 150 Count)

A Yellow Rectangular Box With Black Textdescription Automatically Generated (Tizanidine Hydrochloride Capsules 4mg 150 Count)
This is a description of Tizanidine Hydrochloride Capsules 4mg, a generic medication for Zanaflex. The capsules contain 4.58mg of tizanidine hydrochloride, equivalent to 4mg of tizanidine base. Manufactured by Rubicon Research Private Limited, the packaging includes information on storage conditions and precautions. The product is identified by a blue and white capsule imprinted with a frowhead 044. The text also includes cautionary statements about federal laws regarding the transfer of the drug. Additionally, details such as quantity, lot number, batch number, and product codes are provided for tracking and identification purposes.*
FDA Label Image

Figure 1 (Tizanidine Hydrochloride Capsules Figure 1)

Figure 1 (Tizanidine Hydrochloride Capsules Figure 1)
FDA Label Image

Figure 2 (Tizanidine Hydrochloride Capsules Figure 2)

Figure 2 (Tizanidine Hydrochloride Capsules Figure 2)
The text mentions the dosage of 16 mg and 8 mg of tizanidine and the measurement of improvement in Ashworth Score over time periods post-dose. It may be related to a study, research, or medical documentation focusing on the effectiveness of tizanidine in managing a condition.*
FDA Label Image

Figure 3 (Tizanidine Hydrochloride Capsules Figure 3)

Figure 3 (Tizanidine Hydrochloride Capsules Figure 3)
This text discusses the evaluation of Tizanidine in comparison to a placebo in terms of the mean dose and improvement in Ashworth Score over three study weeks. It mentions the end of titration, end of maintenance, and the last observation carried forward as part of the evaluation process.*
FDA Label Image

Chemical Structural Formula (Tizanidine Hydrochloride Capsules Structure)

Chemical Structural Formula (Tizanidine Hydrochloride Capsules Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.